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Abstract
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for many hematological
conditions. Acute graft-versus-host disease (aGVHD) is a prevalent immune-mediated complication following HSCT.
Current diagnostic biomarkers that correlate with aGVHD severity, progression, and therapy response in graft recipients
are insufficient. Here, we investigated whether epigenetic marks measured in peripheral blood of healthy graft donors
stratify aGVHD severity in human leukocyte antigen (HLA)-matched sibling recipients prior to T cell-depleted HSCT.
Methods: We measured DNA methylation levels genome-wide at single-nucleotide resolution in peripheral blood of
85 HSCT donors, matched to recipients with various transplant outcomes, with Illumina Infinium HumanMethylation450
BeadChips.
Results: Using genome-wide DNA methylation profiling, we showed that epigenetic signatures underlying
aGVHD severity in recipients correspond to immune pathways relevant to aGVHD etiology. We discovered 31
DNA methylation marks in donors that associated with aGVHD severity status in recipients, and demonstrated strong
predictive performance of these markers in internal cross-validation experiments (AUC = 0.98, 95 % CI = 0.96–0.99).
We replicated the top-ranked CpG classifier using an alternative, clinical DNA methylation assay (P = 0.039). In an
independent cohort of 32 HSCT donors, we demonstrated the utility of the epigenetic classifier in the context of a
T cell-replete conditioning regimen (P = 0.050).
Conclusions: Our findings suggest that epigenetic typing of HSCT donors in a clinical setting may be used
in conjunction with HLA genotyping to inform both donor selection and transplantation strategy, with the
ultimate aim of improving patient outcome.
Background
Hematopoietic stem cell transplantation (HSCT) is a
curative therapy for a wide range of hematological disor-
ders and malignancies. Severe immune reactions, in par-
ticular graft-versus-host disease (GVHD), can decrease
HSCT efficiency and survival in patients [1]. Immuno-
suppressive agents that counteract such events confer
further complications, such as opportunistic infections
and cancer recurrence [2].
Acute GVHD (aGVHD) has classically been described
to develop within 100 days after HSCT, but can some-
times occur at later time points. In aGVHD, alloreactive
donor T cells respond to antigens in the host tissues and
damage recipient epithelial cells in skin, liver, and
gastrointestinal tract [3]. T cell depletion of donor graft
provides an efficient strategy of reducing the incidence
of aGVHD, but can delay immune reconstitution and
abrogate beneficial graft-versus-tumor effects [4]. With-
out T cell depletion, aGVHD affects 20–40 % of graft
recipients when the donor and recipient are related, and
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40–70 % when they are not related [5]. The incidence
depends on a number of factors, including relatedness
and degree of human leukocyte antigen (HLA) disparity,
as well as differences in sex, age, and cytomegalovirus
serostatus, between donor and recipient.
Promising novel therapeutic approaches to prevent or
treat GVHD are being developed, including monoclonal
antibodies targeting inflammatory cytokines and small-
molecule inhibitors that alter immune cell trafficking
(reviewed in [1]). In parallel, biomarkers that inform the
risk of development and severity of GVHD are of sub-
stantial clinical importance. Several studies have mea-
sured plasma concentration levels of a number of
different proteins, such as IL2RA and ST2, demonstrat-
ing correlation with responsiveness to treatment [6, 7].
Importantly, all biomarkers thus far characterized are
applied in recipients after HSCT. Biomarkers that guide
transplantation strategy have not yet been identified, but
could provide a valuable approach to improving patient
outcome following HSCT.
Epigenetic factors, such as DNA methylation and post-
transcriptional modification of histones, play a critical
role in regulating gene transcriptional programs that
dictate immune cell fate and function [8]. Epigenetic
mechanisms in circulating immune cells are sensitive to
environmental factors and may contribute to disease
development and progression, alongside genetic pre-
disposition. For example, epigenetic mechanisms have
been uncovered for distinct T cell differentiation path-
ways [9–11], and DNA methylation patterns have
been associated with inflammatory and autoimmune
disease susceptibility, including type 1 diabetes [12],
systemic lupus erythematosus [13], and rheumatoid
arthritis [14].
However, thus far little attention has been paid to the
possible impact of epigenetic factors on HSCT outcomes.
To this end, Rodriguez et al. examined DNA methylation
differences in peripheral blood between donors and recipi-
ents (n = 47 pairs), both pre- and post-HSCT [15]. Global
DNA methylation levels were estimated at CpG sites at
repetitive DNA elements using a pyrosequencing-based
assay. The results suggest that recipients maintain the
donor’s global methylation levels after HSCT. DNA
methylation levels were further measured at promoters of
genes with functions relevant to immune responses in
HSCT. In this analysis, the authors identified subtle DNA
methylation changes at the IFNG, FASLG, and IL10 gene
promoters between recipients developing either no or
mild, and severe aGVHD one month after HSCT.
Differential DNA methylation analyses between HSCT
donors and recipients are impeded by several factors.
First, recipients that are appropriate for HSCT suffer
from a wide range of hematological malignancies. Epi-
genetic dysregulation in cancer etiology is well-described
[16]; therefore, the meaningful comparison of DNA
methylation patterns with regards to HSCT between
healthy donors and patients is unattainable. Second,
blood cells isolated from post-HSCT recipients may ori-
ginate either from the remaining hematopoietic reper-
toire or the donor graft (that is, ‘mixed chimerism’),
complicating the interpretation of the derived epigenetic
signature.
In the present study, we investigated whether distinct
epigenetic marks in peripheral blood of healthy graft
donors delineate aGVHD severity in HLA-matched sibling
recipients prior to HSCT. We measured DNA methyla-
tion levels genome-wide at 414,827 CpG sites at single-
nucleotide resolution in peripheral blood of 85 HSCT
donors, matched to recipients with various transplant out-
comes. We defined a DNA methylation signature that
stratifies graft donors with respect to aGVHD severity
diagnosed in recipients, and replicated the signature with
an alternative DNA methylation assay used in a routine
clinical diagnostics environment. Here, we introduce the
approach of epigenetic typing of HSCT donors to be used
in conjunction with HLA genotyping to inform both
donor selection and transplantation strategy.
Methods
Ethics
The research conformed to the Declaration of Helsinki
and to local regulatory legislation. All HSCT donors and
patients gave written informed consent according to
local institutional guidance and JACIE (Joint Accredit-
ation Committee of the International Society for Cellular
Therapy and the European Group for Blood and Marrow
Transplantation) standards for the analyses performed
and publication of these data. The study was approved
by the UCL Research Ethics Committee (Project ID
7759/001).
Experimental design
The discovery cohort consisted of 85 HLA-identical sib-
ling pairs who underwent reduced-intensity allogeneic
HSCT between June 2000 and November 2012 at either
the University College London Hospital or Royal Free
Hospital (London, UK). Sibling pairs were 10/10 HLA
allele-matched (that is, for HLA-A, -B, -C, -DRB1, and
-DQB1). Donors provided peripheral blood stem cells mo-
bilized by granulocyte-colony stimulating factor (G-CSF).
All recipients received uniform conditioning with fludara-
bine, melphalan, and alemtuzumab [17]. Acute and
chronic GVHD were assessed and graded according to
published criteria [18]. Cyclosporine A was administered
for GVHD prophylaxis. In the absence of GVHD, im-
munosuppression was decreased from three months
after HSCT. The 85 graft donors were matched with
recipients of various transplant outcomes: ‘severe’
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aGVHD (grades III + IV; n = 9), ‘mild’ aGVHD (grades I +
II; n = 37), and no aGVHD (n = 39). To obtain more
equally powered sample groups, we enriched for severe
transplant outcomes.
To assess the initial findings with regards to transplant
conditioning regimen, we identified a validation cohort
consisting of 32 HLA-identical sibling pairs undergoing
T cell-replete HSCT between September 2000 and April
2012 at Hammersmith Hospital (London, UK). One of
three regimens was used: (1) fludarabine alone; (2)
fludarabine, rituximab, and cyclophosphamide; or (3)
lomustine, cytarabine, cyclophosphamide, and etoposide.
Patients received cyclosporine A and methotrexate as
prophylaxis against GVHD. The 32 graft donors were
matched with recipients of the following transplant out-
comes: severe aGVHD (n = 9), mild aGVHD (n = 8), and
no aGVHD (n = 15).
DNA extraction
DNA was extracted from peripheral blood using a
QIAamp DNA Blood BioRobot MDx Kit (QIAGEN) fol-
lowing the manufacturer’s instructions. The DNA con-
centration was assessed using a Qubit dsDNA BR Assay
Kit (Invitrogen).
Illumina Infinium HumanMethylation450 assay
Genomic DNA was bisulfite-converted using an EZ-96
DNA Methylation MagPrep Kit (Zymo Research) ac-
cording to the manufacturer’s instructions. We applied
500 ng or 250 ng of genomic DNA to bisulfite treat-
ment, and eluted purified, bisulfite-converted DNA in
20 μL or 11 μL of M-Elution Buffer (Zymo Research),
respectively. DNA methylation levels were measured
using Infinium HumanMethylation450 assays (Illumina)
following the manufacturer’s protocol. In brief, 4 μL of
bisulfite-converted DNA was isothermally amplified,
enzymatically fragmented, and precipitated. Next, pre-
cipitated DNA was resuspended in hybridization buffer
and dispensed onto Infinium HumanMethylation450
BeadChips (Illumina). To limit batch effects, samples
were randomly distributed across slides and arrays. The
hybridization was performed at 48 °C for 20 h using a
Hybridization Oven (Illumina). After hybridization,
BeadChips were washed and processed through a single-
nucleotide extension followed by immunohistochemistry
staining using a Freedom EVO Robot (Tecan). Finally,
the BeadChips were imaged using an iScan Microarray
Scanner (Illumina).
Illumina Infinium HumanMethylation450 data
preprocessing
The DNA methylation fraction at a specific CpG site
was calculated as β =M/(M +U + 100), for which M and
U denote methylated and unmethylated fluorescent
signal intensities, respectively. The β-value statistic
ranges from absent (β = 0) to complete DNA methylation
(β = 1) at a particular CpG site. We normalized the 450K
array data using Functional Normalization (FunNorm), a
novel between-array normalization method, which is based
on quantile normalization and uses control probes to act
as surrogates for unwanted variation [19, 20]. In addition,
the method entails background correction and dye-bias
normalization using NOOB [21]. Next, we filtered: (1)
probes with median detection P value ≥0.01 in one or
more samples; (2) probes with bead count of less than
three in at least 5 % of samples; (3) probes mapping to sex
chromosomes; (4) non-CG probes; (5) probes mapping to
ambiguous genomic locations [22]; and (6) probes harbor-
ing SNPs at the probed CG irrespective of allele frequency
in the Asian, American, African, and European popu-
lations based on the 1000 Genomes Project (Release
v3, 2011-05-21). All 450K array data preprocessing
steps were carried out using the R package minfi
[20]. Finally, we adjusted for batch effects (Sentrix
ID) using an empirical Bayesian framework [23], as
implemented in the ComBat function of the R pack-
age SVA [24]. The 450K array data generated as part of
this study have been submitted to the European Genome-
phenome Archive (https://www.ebi.ac.uk/ega/) with acces-
sion number EGAS00001001287.
Estimation of differential leukocyte counts
We estimated differential leukocyte counts for each indi-
vidual using an algorithm that is based on regression
calibration [25], and implemented in the R package
minfi [20]. In brief, for each sample the relative pro-
portions of principal leukocyte cell types was inferred
using DNA methylation signatures of an external valid-
ation set consisting of purified leukocytes, specifically
CD3+CD4+ and CD3+CD8+ T lymphocytes, CD19+ B lym-
phocytes, CD56+ natural killer cells, CD14+ monocytes,
and CD15+ granulocytes.
Identification of differentially methylated regions (DMRs)
and positions (DMPs)
We identified DMRs associated with aGVHD severity
using Probe Lasso v6.1 [26]. We applied the following
parameters: lassoStyle =max, lassoRadius = 2000, min-
SigProbesLasso = 2, minDmrSep = 1000, minDmrSize =
0, and adjPVal = 0.1. P values of DMRs were corrected
for multiple testing with the false discovery rate (FDR)
method. To identify DMPs, we fitted a linear regression
model predicting DNA methylation state at each CpG
site as a function of aGVHD severity (severe = 1 vs. no/
mild aGVHD = 0), adjusted for sex, age at graft donation,
and estimated differential cell counts (CD8T + CD4T +
Bcell + NK +Mono + Gran). The DMP analysis was per-
formed using the R package limma [27]. The approach
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uses an empirical Bayes method to moderate the stand-
ard errors of the estimated log-fold changes. P values of
identified DMPs were corrected for multiple testing
using the Bonferroni method.
Annotation of DMRs using the Genomic Regions
Enrichment of Annotations Tool (GREAT)
We analyzed the ontology of genes flanking the identi-
fied DMRs with GREAT v3.0.0 [28], using the standard
parameters: association rule = basal + extension (consti-
tutive 5 kb upstream, 1 kb downstream, up to 1 Mb ex-
tension); curated regulatory domains = included;
background = whole genome.
Assessment of epigenetic classifier performance with
leave-one-out cross-validation (LOOCV)
To assess the performance of the epigenetic classifier, we
used the preprocessed 450K array data set consisting of
85 donors. In each iteration of the LOOCV, one sample
was left out and DMPs were identified using the
remaining dataset (n = 85–1 donor samples). We used
the same linear regression model, covariates, and signifi-
cance thresholds for identifying DMPs as described
above. Significant DMPs were ranked according to their
P values. Then, a nearest shrunken centroid classifier
was trained on the identified DMPs, as implemented in
the R package pamr [29, 30]. The number of cross-
validation folds was specified to the smallest class size,
and a (random) balanced cross-validation was used (de-
fault parameters). The threshold for centroid shrinkage
was set to one. The resulting centroid classifiers were
used to predict aGVHD severity status on the omitted
sample. Finally, classifier performance was evaluated
using receiver operating characteristic (ROC) and area
under the curve (AUC) measures, as implemented in the
R package pROC [31].
Measurement of relative DNA methylation levels using
MethyLight
Genomic DNA was bisulfite-converted using an EZ
DNA Methylation-Gold Kit (Zymo Research) according
to the manufacturer’s instructions. PCR primers and
probes for MethyLight analyses were designed specific-
ally for bisulfite-converted DNA (5′ to 3′ plus strand)
using ABI Primer Express v3. All oligonucleotides were
synthesized by Metabion. Details with regards to PCR
primers and probes used in this study are provided in
Additional file 1. The reaction for the CpG of interest
was assayed alongside a reference, the collagen 2A1 gene
(COL2A1), to normalize for input DNA. Specificity of
the reactions for methylated DNA was confirmed using
M.SssI-treated human peripheral blood lymphocyte
DNA (fully methylated positive control), whole-genome
amplified DNA (unmethylated negative control), and a
non-template control. The efficiencies of primers were
assessed using a five-log serial dilution of M.SssI-treated
human genomic standard. In addition, an agarose gel
was run to ensure a single and appropriately sized PCR
product. The fraction of fully methylated molecules at a
specific locus was represented as percentage of methyl-
ated reference (PMR). First, all Ct-values were interpo-
lated from the standard curve based on a four-fold
dilution of M.SssI-treated DNA. Then, we calculated
PMR values by dividing the target CpG/reference Ct-ra-
tio of a sample by the CpG/reference Ct-ratio of the
M.SssI-treated DNA, multiplied by 100. All MethyLight
reactions were performed on a 6FLX Real-Time PCR
System (Life Technologies). DNA methylation thresholds
with the maximal specificity and sensitivity were deter-
mined at the coordinates closest to the top-left part of
the ROC curves (best.method = closest.topleft), as imple-
mented in the R package pROC [31].
Software for statistical analyses
All statistical analyses described in this study were per-
formed using R v3.1.1 and Bioconductor v3.0.
Results
Characterization of distinct genome-wide DNA
methylation signatures in HSCT donors
We investigated a total of 85 HLA-identical HSCT
donor-recipient sibling pairs. We focused on sibling
pairs to minimize the contribution from genetic factors
in our analyses. All patients undergoing HSCT received
reduced-intensity (non-myeloablative) T cell-depleted
conditioning using in vivo alemtuzumab. The T cell-
depleted platform was chosen in the first instance in
order to try to identify major drivers of aGVHD in the
context of a platform with a relatively low incidence of
GVHD. Sample selection was enriched for severe trans-
plant outcomes to balance sample groups, that is,
‘severe’ aGVHD (grades III + IV; n = 9), ‘mild’ aGVHD
(grades I + II; n = 37), and no aGVHD (grade 0; n = 39).
Details about sample selection are described in the
Methods section, and demographics of HSCT donors and
recipients are provided in Table 1. An overview of the
study design is illustrated in Fig. 1.
We measured genome-wide DNA methylation levels
in peripheral blood of HSCT donors using Illumina Infi-
nium HumanMethylation450 BeadChips (‘450K arrays’).
The two-color array allows the assessment of DNA
methylation status at over 485,000 CpG sites at single-
nucleotide resolution. The assay covers 99 % of RefSeq
genes with an average of 17 CpG sites per gene region,
and 96 % of CpG islands [32]. Array data preprocessing
was performed using established analytical methods
(Methods). Array probes were filtered with stringent
quality criteria, leaving a total of 414,827 CpG sites for
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subsequent statistical analyses. A summary of the
quality assessment of the 450K array data is shown in
Additional file 2.
We performed multidimensional scaling (MDS) based
on all measured CpG sites to assess the degree of similar-
ity of individual HSCT donors. HSCT donors matched to
healthy recipients and those matched to recipients diag-
nosed with mild aGVHD could not be discriminated using
MDS (Additional file 2). Consequently, these two sample
groups were combined for subsequent analyses. The ana-
lytical approach identified a DNA methylation signature
that stratifies donors paired with recipients with severe
aGVHD (Additional file 2).
To characterize the DNA methylation signatures
underlying aGVHD severity, we identified DMRs be-
tween donors paired with no/mild aGVHD and severe
aGVHD. DMRs have been shown to more likely locate
near differentially expressed genes compared to differen-
tially methylated single CpG sites [20]. DMRs were iden-
tified using the Probe Lasso algorithm [26], which
applies a dynamic window based on probe annotation
and density to record neighboring significant CpG sites
and determine discrete DMR boundaries. A total of 453
DMRs at an FDR of less than 10 % were discovered. We
annotated the genes flanking these DMRs using the
Genomic Regions Enrichment of Annotations Tool
(GREAT) [28], and observed enrichment in the ontology
terms ‘MHC class II receptor activity’ (GO Molecular
Function; P = 3.53 × 10–5, FDR-corrected binomial
test), ‘MHC class II protein complex’ (GO Cellular
Component; P = 4.46 × 10–6), ‘antigen processing and
presentation’ (MSigDB Gene Sets Canonical Pathway;
P = 2.08 × 10–6), ‘MHC classes I/II-like antigen recog-
nition protein’ (InterPro; P = 1.97 × 10–4), among other
Table 1 Demographics of HSCT donors and recipients in the
discovery and validation cohorts
Discovery cohort Validation cohort
(n = 85 pairs) (n = 32 pairs)
Donors Recipients Donors Recipients
Sex
Female 41 27 14 7
Male 44 58 18 25
Age at transplant (years)
Median 48 52 53 55
Range 14–72 21–66 22–71 23–64
CMV serostatus
Positive 38 43 14 11
Negative 31 32 16 21
NA 16 10 2 0
Max. acute GVHD
Absent – 39 – 15
Grade I ('mild') – 24 – 3
Grade II ('mild') – 13 – 5
Grade III ('severe') – 8 – 7
Grade IV ('severe') – 1 – 2
Max. chronic GVHD
Absent – 54 – 2
Limited – 21 – 10
Extensive – 9 – 3
NA – 1 – 17
Diagnosis
Acute lymphoblastic
leukemia
– 1 – 1
Acute myeloid leukemia – 17 – 8
Chronic granulomatous
disease
– 1 – 0
Chronic lymphocytic
leukemia (CLL)
– 11 – 0
Chronic myeloid leukemia
(CML)
– 0 – 3
Chronic myelomonocytic
leukemia
– 1 – 0
Hodgkin lymphoma – 9 – 4
Myelodysplasia (MDS) – 2 – 0
MDS/CML/CLL – 1 – 0
Myelofibrosis – 0 – 2
Myeloproliferative
syndromes/MDS
– 0 – 2
Myeloma – 3 – 0
Non-Hodgkin lymphoma – 37 – 8
Other – 0 – 4
NA – 2 – 0
Table 1 Demographics of HSCT donors and recipients in the
discovery and validation cohorts (Continued)
Sibling pairs Sibling pairs
Sex match (donor/recipient)
Male/male 30 14
Female/female 13 3
Male/female 14 4
Female/male 28 11
CMV match (donor/recipient)
Negative/negative 18 13
Positive/positive 25 8
Negative/positive 13 3
Positive/negative 13 6
NA 16 2
Detailed information regarding criteria for study inclusion is provided in the
Methods section. Note that the diagnosis ‘Non-Hodgkin lymphoma’ includes
various disease subtypes.
CMV cytomegalovirus, NA data not available
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relevant terms (Additional file 3). Taken together, these re-
sults indicate that healthy HSCT donors whose recipients
develop severe aGVHD exhibit a specific DNA methyla-
tion signature, which correlates with known molecular
processes relevant to GVHD pathobiology.
Identification of differentially methylated positions
associated with aGVHD severity
Next, we determined DMPs in HSCT donors associated
with aGVHD severity in recipients that may be exploited
as biomarkers for clinical diagnostics. We used a linear
regression model predicting DNA methylation state at
each CpG site as a function of aGVHD severity status,
that is, severe vs. no/mild aGVHD diagnosed in matched
graft recipients. In the regression model, we adjusted for
sex, age at graft donation, and estimated relative propor-
tions of major leukocyte cell types (Methods). We iden-
tified 31 DMPs that achieved a P value <0.05 after
Bonferroni correction. To ascertain DMPs of potential
biological significance, as well as permit validation using
a semi-quantitative DNA methylation assay applicable
for routine clinical testing, we only considered DMPs
with a DNA methylation difference of at least ±5 %
(Table 2). Strikingly, four top-ranked DMPs (that is,
cg20475486, cg10399005, cg07280807, and cg09284655)
form a DMR with consistent DNA hypomethylation in
donors matched to recipients with severe aGVHD com-
pared to donors paired with recipients with no/mild
aGVHD (Fig. 2a). This locus was also identified as one
of the top-ranking DMRs using the Probe Lasso algo-
rithm (P = 4.55 × 10–31; rank = 2).
To estimate the epigenetic classifier performance, we
used leave-one-out cross-validation (LOOCV). In brief,
one donor sample was left out in each iteration of the
LOOCV, and DMPs were identified on the remaining
sample cohort as described above. Then, a nearest
shrunken centroid classifier was trained on the identified
DMPs (Methods). The resulting classifiers were used to
predict aGVHD severity status on the sample that was
left out. Centroid classifier performance was evaluated
by means of ROC curves and summarized by AUC
values. Over the 85 iterations, the mean AUC was 0.98
(95 % confidence interval = 0.96–0.99; Fig. 2b). Import-
antly, all four DMPs contained within the DMR (Fig. 2a)
were selected in over 90 % of iterations of the LOOCV
classifier (Table 2). Our data indicate discovery of
discrete DMPs that discriminate aGVHD severity status,
and demonstrate strong predictive performance in in-
ternal cross-validation experiments.
Replication of top-ranked differentially methylated posi-
tions using a clinical biomarker assay
Following the discovery of DMPs using 450K arrays, we
aimed to replicate the top-ranked CpG sites using a semi-
quantitative DNA methylation assay, MethyLight. This
well-established assay uses PCR amplification of bisulfite-
converted DNA in combination with fluorescently-labeled
probes that hybridize specifically to a fully methylated
DNA sequence [33]. The resulting data is presented as a
percentage relative to an M.SssI-treated, fully methylated
DNA reference sample (PMR). While the quantitative
accuracy is lower compared to Illumina Infinium and
next-generation DNA sequencing-based assays, Methy-
Light can be readily translated into a clinical setting at
relatively low cost [34, 35].
We focused our replication efforts on the highly dis-
criminative DMPs located at the DMR on chromosome
14q24.2 (Table 2; Fig. 2a). We designed MethyLight re-
actions targeting three DMPs, cg20475486, cg10399005,
and cg07280807. Through thorough assessment of the
Fig. 1 Overview of the study design. We aimed to identify specific epigenetic marks in peripheral blood of healthy graft donors that delineate
aGVHD severity in HLA-matched sibling recipients prior to HSCT. At the discovery stage, we assessed genome-wide DNA methylation levels in
peripheral blood of 85 HSCT donors, matched to recipients with various transplant outcomes, that is, ‘severe’ aGVHD (grades III + IV; n = 9) and
‘no/mild’ aGVHD (grades 0, I + II; n = 76). HSCT recipients received reduced-intensity (non-myeloablative) T cell-depleted conditioning using in vivo
alemtuzumab. At the replication stage, we used a semi-quantitative DNA methylation assay, MethyLight, which can be easily used in a clinical
setting. We validated the top-ranked differentially methylated positions associated with aGVHD severity status in donors in the context of both
T cell-depleted and T cell-replete conditioning regimens for HSCT
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performance characteristics of the individual reactions
(Methods), we identified cg20475486 with the highest
PCR efficiency. Consequently, we measured relative DNA
methylation levels at cg20475486 in 63 of the previous 85
HSCT donor samples, for which sufficient material was
available. We replicated the observed DNA hypome-
thylation phenotype in donors paired with recipients
diagnosed with severe aGVHD (P = 0.039, Wilcoxon
rank-sum test; Fig. 3a). At a DNA methylation thresh-
old with the maximal specificity and sensitivity, the
AUC was 0.74 (Fig. 3b). Together, our results suggest
technically robust identification of DMPs associated
with aGVHD severity using both Infinium and Methy-
Light assays.
Validation of epigenetic classifiers in donors in the
context of T cell-replete HSCT
The discovery and replication of DMPs associated with
aGVHD severity was carried out in donors matched to
recipients that were subjected to T cell depletion as part
of their transplant conditioning regimen. We next ex-
plored whether the identified epigenetic classifier could
Table 2 Significant DMPs associated with aGVHD severity status
Rank DMP Adj. P value Δβ-value Chr. Position Gene Feature CpG context LOOCV
1 cg20475486 1.38 × 10−3 −0.180 14 70,317,075 – IGR Island 85
2 cg10399005 1.62 × 10−4 −0.162 14 70,316,898 – IGR Island 85
3 cg16925210 1.60 × 10−5 0.130 2 216,946,718 PECR TSS200 Island 85
4 cg00762468 7.61 × 10−6 0.066 16 103,568 POLR3K 1stExon Island 85
5 cg26758857 1.07 × 10−7 −0.062 22 36,649,135 APOL1 5′UTR – 85
6 cg21752471 8.92 × 10−4 −0.061 5 133,861,794 PHF15 TSS200 Island 85
7 cg21459486 5.14 × 10−4 −0.060 13 112,885,426 – IGR – 85
8 cg16495818 2.05 × 10−5 −0.055 11 73,306,367 FAM168A 5′UTR Shelf 85
9 cg16276523 5.29 × 10−4 −0.094 1 161,049,579 PVRL4 Body Island 84
10 cg19558933 5.11 × 10−3 −0.129 11 134,632,242 – IGR Island 82
11 cg00087067 9.63 × 10−3 0.071 5 5,265,509 ADAMTS16 Body – 82
12 cg14099595 1.62 × 10−2 0.067 5 145,717,283 POU4F3 TSS1500 Shore 82
13 cg07464977 6.69 × 10−3 −0.062 5 2,097,136 – IGR – 82
14 cg11364888 8.50 × 10−3 −0.055 12 116,920,304 – IGR – 82
15 cg24599107 9.57 × 10−3 −0.073 1 161,049,443 PVRL4 Body Island 81
16 cg07280807 8.94 × 10−3 −0.151 14 70,317,239 – IGR Island 80
17 cg14546466 2.49 × 10−2 −0.077 2 11,796,974 – IGR Island 80
18 cg03481039 8.60 × 10−3 −0.065 11 116,662,012 APOA5 Body Shore 80
19 cg03896685 2.62 × 10−2 −0.062 7 65,512,561 – IGR Shelf 80
20 cg00245850 1.78 × 10−2 0.060 8 143,925,513 GML Body – 80
21 cg09284655 1.17 × 10−2 −0.152 14 70,317,228 – IGR Island 79
22 cg10287485 2.20 × 10−2 0.090 11 69,473,145 – IGR Shelf 79
23 cg19704238 1.55 × 10−2 0.058 10 85,900,022 GHITM 5′UTR Shore 79
24 cg09282654 3.33 × 10−2 0.070 7 123,563,992 SPAM1 TSS1500 – 75
25 cg16701890 3.57 × 10−2 0.064 2 119,906,008 – IGR – 73
26 cg04664342 3.80 × 10−2 −0.107 17 4,685,905 TM4SF5 Body Island 65
27 cg20307347 4.06 × 10−2 −0.119 2 231,734,563 ITM2C Body Shelf 58
28 cg19311448 4.17 × 10−2 −0.075 2 11,797,017 – IGR Island 45
29 cg09852744 4.55 × 10−2 0.058 6 158,732,256 TULP4 TSS1500 – 39
30 cg16398628 4.46 × 10−2 0.090 10 91,011,689 LIPA TSS200 Island 32
31 cg20585841 4.57 × 10−2 −0.164 8 102,729,926 NCALD Body – 21
DMPs achieving a P value <0.05 after Bonferroni correction and a DNA methylation difference of at least ±5 % are reported. DMPs are ranked according to their
recurrence in the LOOCV, for which a total of 85 iterations were performed, and their absolute DNA methylation difference. DNA methylation differences were
calculated as follows: mean β-values of HSCT donors matched to recipients with severe aGVHD – mean β-values of HSCT donors matched to recipients with no/
mild aGVHD. The four highlighted DMPs on chromosome 14q24.2 form a region with consistent DNA hypomethylation in graft donors matched to recipients with
severe aGVHD compared to donors paired with recipients with no/mild aGVHD (Fig. 2a). Chromosomal positions are reported in genome build = hg19
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also be used in the context of T cell-replete HSCT (that
is, without the application of in vivo alemtuzumab). We
identified an independent sample cohort of 32 HLA-
identical HSCT donor-recipient sibling pairs. As before,
patients were selected based on transplant outcomes to
obtain evenly numbered sample groups, that is, severe
aGVHD (grades III + IV; n = 9), mild aGVHD (grades
I + II; n = 8), and no aGVHD (grade 0; n = 15). Further
details about sample selection and characteristics of
HSCT donor-recipient sibling pairs are provided in
the Methods section and Table 1, respectively.
In agreement with the data obtained in donors in the
context of T cell-depleted HSCT, we confirmed the
DNA hypomethylation phenotype at the top-ranked
DMP cg20475486 (P = 0.050, Wilcoxon rank-sum test;
Fig. 3c). The area under the ROC curve was 0.73 at the
DNA methylation threshold with the maximal specificity
and sensitivity (Fig. 3d). In summary, we validated the
top-ranked DMP associated with aGVHD severity status
in donors in relation to both T cell-depleted and T cell-
replete conditioning regimens for HSCT. Our findings
describe the first epigenetic classifier for the identifica-
tion of donors with an intrinsically increased allore-
sponse prior to HSCT, identifying donor grafts more
appropriate to undergo T cell depletion to reduce
aGVHD incidence.
Biological significance of DMR associated with aGVHD
severity on chromosome 14q24.2
The DMR harboring the four top-ranked CpG classifiers
(Fig. 2a) map to a CpG island at an intergenic region on
chromosome 14q24.2. To investigate the potential func-
tional role of this DMR, we annotated the genomic locus
using available epigenomic reference datasets provided
by the NIH Roadmap Epigenomics Project [36]. Specific-
ally, we examined chromatin state maps of 22 primary
hematopoietic cell types. Chromatin states are defined as
spatially coherent and biologically meaningful combina-
tions of distinct chromatin marks. These are systematic-
ally computed by exploiting the correlation of such
marks, e.g., histone modifications, DNA methylation,
and chromatin accessibility [37, 38]. This approach has
recently been extended to include prediction (or ‘imput-
ation’) of additional chromatin marks [39].
The annotation with both primary and imputed
chromatin state maps revealed that the DMR is lo-
cated at an active transcription start site or poised
promoter in G-CSF-mobilized CD34+ hematopoietic
stem cells, and a Polycomb-repressed region in CD3+
T cells of peripheral blood (Additional file 4). The
closest annotated gene is SMOC1 (SPARC related
modular calcium binding 1), located 3.77 kb upstream
of the top-ranked DMP cg20475486 (Table 2).
Fig. 2 Identification of DMPs associated with aGVHD severity. a Genomic locus on chromosome 14q24.2 harboring four top-ranked DMPs associated
with aGVHD severity. A DNA hypomethylation phenotype was observed in HSCT donors matched to recipients with severe aGVHD (red points)
compared to donors paired with recipients with no/mild aGVHD (blue points). Lines represent the means of the measured DNA methylation levels
(β-values) across HSCT donors. Statistically significant DMPs are indicated with a black triangle. Annotation of all significant DMPs is provided in Table 2.
b ROC measures evaluating the epigenetic classifier performance. LOOCV was used to assess the classifier performance (Methods). Over 85 iterations
of the LOOCV, the mean AUC was 0.98 (95 % confidence interval = 0.96–0.99), with a maximal specificity and sensitivity of 0.93 and 0.93, respectively
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SMOC1 does not have a previously reported function
in inflammatory or immune response pathways, and
the evidence provided by the chromatin state maps
suggests that SMOC1 is unlikely to be the relevant
target gene at this locus. Instead, the DMR may pin-
point a transcription start site of a novel, un-
annotated gene or transcript that potentially plays a
role in T cell lineage development.
Discussion
GVHD is a condition in which both prevention and
treatment are associated with significant costs and mor-
bidities. In this study, we derived the first HSCT donor-
specific DNA methylation signature that predicts the
incidence of severe aGVHD in HLA-matched sibling re-
cipients. Following a genome-wide survey in 85 HSCT
donors using 450K arrays, we replicated the identified
Fig. 3 Validation of top-ranked DMP cg20475486 using a clinical biomarker assay. Replication of the top-ranked DMP associated with aGVHD
severity, cg20475486, using a semi-quantitative DNA methylation assay. a Box-and-whisker plot of DNA methylation values in graft donors in T
cell-depleted HSCT (initial discovery cohort). We replicated the DNA hypomethylation phenotype in HSCT donors matched to recipients with se-
vere aGVHD compared to no/mild aGVHD (P = 0.039, Wilcoxon rank-sum test). b At a relative DNA methylation threshold of 8.295 (dotted line),
the AUC was 0.74 with a maximal specificity and sensitivity of 0.75 and 0.71, respectively. c Box-and-whisker plot of DNA methylation values in
graft donors in T cell-replete HSCT (that is, without the application of in vivo alemtuzumab). In an independent sample cohort, we confirmed the
observed DNA methylation phenotype, suggesting the epigenetic classifier is also effective in the context of a T cell-replete conditioning
regimen (P = 0.050). For two samples, Ct-values could not be detected in the MethyLight experiments. d At a threshold of PMR = 17.73 (dotted
line), the area under the ROC curve was 0.73 with a maximal specificity and sensitivity of 0.71 and 0.78, respectively
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epigenetic signature associated with aGVHD severity
status in 63 donors using MethyLight, a low-cost assay
that is applicable for routine clinical diagnostics. Fur-
thermore, we demonstrated the utility of the epigenetic
classifier in the context of a T cell-replete conditioning
regimen in an additional 32 HSCT donors.
We note that our study has limitations. Our DNA
methylation analysis was carried out in peripheral blood,
a substantially heterogeneous tissue. Cellular heterogen-
eity is a potential confounder in differential DNA methy-
lation analyses [14, 40]. While we carefully assessed and
controlled for differential leukocyte composition using
statistical methods (Methods; Additional file 5), we can-
not exclude the possibility that some of the identified
DMPs are due to differential counts of cellular subpopu-
lations that are not accounted for by the statistical infer-
ence. Indeed, previous studies have shown that most of
the potential alloreactivity of a donor graft resides within
the naïve T cell pool [41]. Therefore, differences in cellu-
lar composition of a subset of alloreactive T cells may
even be anticipated. However, it should be noted that
even if the associations are observed as a result of differ-
ential cell composition, this does not affect the validity
of our finding as a valuable classifier.
The discriminatory performance of the presented epi-
genetic classifier, which consisted of only the CpG classi-
fier cg20475486 at the replication stage, was reduced
compared to the classifier panel consisting of multiple
CpG sites at the discovery stage. We investigated
whether variation in distinct HSCT donor groups (that
is, donors matched to recipients with no complications,
and those matched to mild aGVHD) caused the reduced
performance, but could not substantiate this hypothesis
(Additional file 6). Instead, the reason could be tech-
nical, because the 450K array platform measured DNA
methylation levels at cg20475486 in single-nucleotide
resolution, whereas MethyLight assessed the levels
across eight linked CpGs (Additional file 1). Based on
the combined graft donor pool across both T cell-
depleted and T cell-replete HSCT (n = 93 donors;
PMR = 8.295), the AUC was 0.69 with a maximal spe-
cificity and sensitivity of 0.81 and 0.56, respectively.
The findings of our study will need validating in larger co-
horts of HSCT donors that are matched to recipients with
severe aGVHD. Also, we acknowledge that additional
CpG classifiers are required to allow for effective routine
clinical testing of graft donors prior to HSCT. Such add-
itional CpG sites can be collated to constitute a more po-
tent classifier panel, for example by drawing from the list
of identified DMPs (Table 2). This strategy has previously
been applied in an epigenetic biomarker panel for renal
cell carcinoma [42] and active ovarian cancer [43] using
20 and even 2,714 distinct CpG classifiers, respectively. In
addition, an independent discovery stage for HSCT
donors whose recipients undergo T cell-replete condition-
ing may reveal a different set of DMPs.
The 450K array platform used for DNA methylation
profiling holds a fixed, predesigned content covering less
than 2 % of all annotated CpG sites. It is conceivable
that CpG sites that are not captured by the array are
more informative. Our study design also required two
sample batches, which necessitated batch effect correc-
tion, potentially reducing the number of informative
DMPs (Methods). Nonetheless, if combined with an
alternative assay for replication of initial discoveries,
450K arrays are the current assay of choice for genome-
wide surveys due to their quantitative, robust, and scal-
able assessment of DNA methylation levels.
We recognize that the presented epigenetic changes
associated with aGVHD severity status may in fact
merely mediate genetic risk factors for HSCT. We omit-
ted array probes from statistical analyses that contained
common genetic variants that likely influence DNA
binding (Methods), but DNA methylation levels may be
mediated by genetic variants in proximity, that is, repre-
sent DNA methylation quantitative trait loci (met-
QTLs). Systematic met-QTL mapping efforts in HSCT
donors with matched genotypic and epigenotypic data-
sets, combined with causal inference methods [14], are
necessary to investigate this possibility further, but are
beyond the scope of this study.
We provide evidence that DNA methylation signatures
in graft donors associated with aGVHD severity in recip-
ients correlate with well-characterized gene sets and mo-
lecular processes relevant to GVHD etiology, such as
MHC class II restriction (Additional file 3). However,
the functional importance of the specific DMR contain-
ing the four top-ranked CpG classifiers on chromosome
14q24.2 (Fig. 2a) is obscure and warrants additional ex-
perimental investigation. Annotation using chromatin
state maps showed that the DMR maps to an active
transcription start site in CD34+ hematopoietic stem
cells, and a Polycomb-repressed regulatory element in
CD3+ T cells (Additional file 4). Indeed, Polycomb pro-
teins play a role in preventing the inappropriate hyperac-
tivation of T cells in the setting of GVHD [44]. Future
studies should delineate the DNA methylation signature
in homogeneous T cell subsets and at various stages of T
cell formation and development. International consortia,
in particular BLUEPRINT [45], add further reference
epigenomes of hematopoietic cell types, including many
progenitor populations.
Conclusions
Our results are the first to identify an epigenetic signa-
ture in healthy graft donors that can predict aGVHD in
recipients. The findings suggest the possible use of epi-
genetic profiling in conjugation with genetic profiling to
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improve donor selection prior to HSCT and inform im-
munosuppressive transplant conditioning, with the para-
mount goal of improving patient outcomes. Looking
ahead, we plan to further develop this first epigenetic
classifier and its utility to also include unrelated HSCT
donors, who constitute the majority of the allogeneic
HSCT donor pool, and for which the incidence of
aGVHD is most prevalent.
Additional files
Additional file 1: PCR primers and probes used in MethyLight
replication experiments. A total of three MethyLight reactions were
designed, which targeted top-ranked DMPs associated with aGVHD severity:
cg10399005, cg20475486, and cg07280807. Of these reactions, cg20475486
achieved the highest PCR efficiency and was subsequently used in
validation experiments (highlighted in gray). Start and end positions of
primer and probes are noted in relation to the design start coordinates.
Chromosomal positions are reported in genome build = hg19. (PDF 110 kb)
Additional file 2: Quality assessment of the Illumina Infinium
HumanMethylation450 assay. The quality of the 450K array data was
assessed after normalization, probe filtering, and batch correction (for details
see Methods). (a) Density of DNA methylation β-values. (b) Multidimensional
scaling (MDS) indicates the similarities and differences of samples
by calculating the Euclidean distances between samples based on all
CpG sites, and then projecting these distances into 2D coordinates.
We found Dimension 4 to associate with aGVHD severity, accounting for
3 % of the total variance. HSCT donors matched to healthy recipients and
those matched to recipients diagnosed with mild aGVHD could not be
stratified using MDS. Therefore, these two sample groups were combined
for subsequent analysis. (c) Singular value decomposition (SVD) determines
the nature of the largest components of variation (Teschendorff AE et al.
PLoS One. 2009;4:e8274). We assessed the first six principal components
(PCs), and correlated these to phenotypic factors of donors (e.g., sex, age at
transplant, and CMV serostatus), phenotypic factors of recipients (e.g.,
aGVHD status and severity), factors related to the experimental setup
(e.g., Sentrix ID, sample plate, and sample well), as well as internal control
parameters (e.g., bisulfite conversion efficiency). DNA methylation age
(‘DNAm age’) was predicted based on the raw DNA methylation
data using the DNA Methylation Age Calculator (https://dnamage.
genetics.ucla.edu/), as described by Horvath (Horvath S. Genome Biol.
2013;14:R115). The phenotypic factor ‘transplant date’ denotes the year
of the day of the graft transplant (day 0). We found PC4 and PC5 to most
strongly correlate with aGVHD severity, achieving a significance level of
P <0.01 and P <1 × 10−5, respectively. (PDF 507 kb)
Additional file 3: Ontology annotation of genes flanking DMRs
using GREAT. We report the ontology of genes flanking the 453
identified DMRs. Specifically, we indicate all enriched terms in the
binomial test over genomic regions at an FDR of less than 5 %.
(PDF 107 kb)
Additional file 4: Annotation of top-ranked DMPs using epigenomic
reference datasets. The genomic locus on chromosome 14q24.2
(position = 70,261,006–70,349,114; genome build = hg19) harboring the
top-ranked DMR is shown using the WashU Epigenome Browser v40.0.0
(http://epigenomegateway.wustl.edu/browser/). The top-ranked DMR
containing CpG classifiers of aGVHD severity (Table 2) is located at a
CpG island (position = 70,316,847–70,317,240; indicated with an orange
arrow). RefSeq and Gencode v17 genes, as well as CpG islands, are shown
in the bottom panel of the figure. A total of 50 epigenomic reference
tracks provided by the NIH Roadmap Epigenomics Project are displayed.
Specifically, we show both the primary and imputed chromatin state maps
in 22 primary hematopoietic cell types. The highlighted DMR overlaps
with an active transcription start site (red) or poised promoter (pink) in
G-CSF-mobilized CD34+ hematopoietic stem cells, and a Polycomb-
repressed region in CD3+ T cells of peripheral blood. (PDF 960 kb)
Additional file 5: Estimation of differential leukocyte counts. For
each sample, the composition of major leukocyte cell types was
estimated using DNA methylation signatures of an external reference set
consisting of purified leukocytes (Houseman EA et al. BMC Bioinformatics.
2012;13:86). The leukocyte composition was grouped for each measured
cell type, and stratified for donors paired with healthy recipients (n = 39),
recipients developing mild (n = 37) and severe aGVHD (n = 9). We did not
observe significant differences (P <0.05) in cellular composition between
the sample groups. For each cell type, the bar indicates the median of
the composition estimate. Error bars indicate 95 % confidence intervals. P
values were calculated using a Kruskal-Wallis rank-sum test. (PDF 235 kb)
Additional file 6: Box-and-whisker plots of DNA methylation values
in graft donors in the discovery cohort assessed using MethyLight
and 450K arrays. Only HSCT donors of the discovery cohort that
were profiled on both assay platforms are shown. We identified a
DNA hypomethylation phenotype at the top-ranked DMP cg20475486
in graft donors matched to recipients with severe aGVHD. HSCT donors
matched to healthy recipients and those matched to recipients diagnosed
with mild aGVHD could not be discriminated. (PDF 256 kb)
Abbreviations
aGVHD: acute graft-versus-host disease; AUC: area under the curve; CGI:
CpG island; DMP: differentially methylated position; DMR: differentially
methylated region; DNAm: DNA methylation; FDR: false-discovery rate;
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